[Featured Stock] Green Cross MS Rises Over 12% on Monkeypox Skin Infection Cases Increase

[Asia Economy Reporter Kwon Jae-hee] Green Cross MS, a stock related to 'monkeypox,' is showing strong performance in early trading on the 24th. As human infection cases of 'monkeypox' have been discovered worldwide, attention is returning to bio stocks that had been quiet since the COVID-19 endemic.

According to the Korea Exchange on the 24th, as of 10:02 AM, Green Cross MS is trading at 9,810 KRW, up 12.24% compared to the previous trading day. Green Cross MS also closed the previous day at 8,740 KRW, up 25.57% from the previous trading day.

Green Cross MS is classified as a monkeypox-related stock due to its past research history in developing an attenuated smallpox vaccine. Currently, monkeypox cases have been reported in 15 countries. Although similar to smallpox, it is known to have relatively lower transmissibility and severity. Major symptoms include fever, chills, and muscle pain, with characteristic vesicular rashes similar to chickenpox appearing primarily on the hands and throughout the body.